4-乙氧基苯氧基乙酸 | 5327-91-3

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-乙氧基苯氧基乙酸
• 中文别名: 2-(4-乙氧基苯氧基)乙酸
• 英文名称: (4-ethoxyphenoxy)acetic acid
• 英文别名: (4-ethoxy-phenoxy)-acetic acid；(4-Aethoxy-phenoxy)-essigsaeure；4-Ethoxyphenoxyacetic acid；2-(4-ethoxyphenoxy)acetic acid
• CAS: 5327-91-3
• 化学式: C₁₀H₁₂O₄
• mdl: MFCD03419318
• 分子量: 196.203
• InChiKey: NSVKLONIKJVUPZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  4-乙氧基苯氧基乙酸 在 氯化亚砜 作用下， 生成 (4-ethoxy-phenoxy)-acetyl chloride
  参考文献：
  名称：

  Nasarow; Tscherkasowa, Zhurnal Obshchei Khimii, 1958, vol. 28, p. 122,124, 125; engl. Ausg. S. 122, 123, 125

  摘要：

  DOI：
• 作为产物：
  描述：

  4-乙氧基苯酚 、 氯乙酸 在 sodium hydroxide 作用下， 生成 4-乙氧基苯氧基乙酸
  参考文献：
  名称：

  Nametkin et al., Zhurnal Obshchei Khimii, 1951, vol. 21, p. 327,328; engl. Ausg. S. 359, 360

  摘要：

  DOI：

文献信息

• ROLES OF MODULATORS OF INTERSECTIN-CDC42 SIGNALING IN ALZHEIMER'S DISEASE
  申请人：East Carolina University

  公开号：US20190091184A1

  公开（公告）日：2019-03-28

  Methods of treating Alzheimer's disease and other neurodegenerative and/or neurocognitive and/or neurodevelopmental diseases are described. The methods comprise the administration of compounds that modulate an activity of cell division control protein 42 (Cdc42), such as the interaction between Cdc42 and intersectin (ITSN). Exemplary modulator compounds include thioureas, disulfonamides of fused aromatic systems (e.g., benzofuran), and acyl hydrazones, among others. Some of the modulator compounds act as activators of Cdc42, while others act as inhibitors. In some cases, the modulator compound has dual functionality and the ability of the modulator compound to act as an inhibitor or activator depends on whether or not Cdc42 is already activated in a particular disease stage or biological environment by an upstream activating signal of Cdc42.

  描述了治疗阿尔茨海默病和其他神经退行性和/或神经认知和/或神经发育疾病的方法。这些方法包括给予调节细胞分裂控制蛋白42（Cdc42）活性的化合物，例如Cdc42与交叉素（ITSN）之间的相互作用。示例调节剂化合物包括硫脲、融合芳香系统的二磺酰胺（例如苯并呋喃）和酰基肼等。其中一些调节剂化合物作为Cdc42的激活剂，而另一些作为抑制剂。在某些情况下，调节剂化合物具有双重功能，调节剂化合物作为抑制剂或激活剂的能力取决于Cdc42是否已经通过Cdc42的上游激活信号在特定疾病阶段或生物环境中被激活。
• ACTIVATOR OF ADIPONECTIN RECEPTOR
  申请人：THE UNIVERSITY OF TOKYO

  公开号：US20160214967A1

  公开（公告）日：2016-07-28

  An AdipoR activator for activating both AdipoR1 and AdipoR2 is provided. A compound represented by the following formula (1), wherein A is a substituted or unsubstituted aryl group or the like, Y 1 is (CHR 2 ) a — or the like, X is CH or N, R 1 is a C 1-7 alkyl group, m is an integer of 0-4, Y 2 is *—O—CH 2 —CONH—, *—CONH—(CH 2 ) b —CO— or the like, Z is a cyclic group, B may be a substituent of the cyclic group represented by Z, and n is an integer of 0-3.

  提供了一种用于激活AdipoR1和AdipoR2的AdipoR激活剂。以下式（1）表示的化合物，其中A是取代或未取代的芳基或类似物，Y1是（CHR2）a—或类似物，X是CH或N，R1是C1-7烷基基团，m是0-4的整数，Y2是*—O—CH2—CONH—，*—CONH—（CH2）b—CO—或类似物，Z是环基团，B可以是Z代表的环基团的取代基，n是0-3的整数。
• Method of modifying taste
  申请人：TATE & LYLE PUBLIC LIMITED COMPANY

  公开号：EP0159864A2

  公开（公告）日：1985-10-30

  The sweetness of an ingestible product or oral composition containing a sweetening sugar or sugar alcohol in relatively large quantities can be reduced and/or the flavour enhanced by incorporation of at least one compound of the general formula (I) in which m represents 0 or 1, A represents a homocyclic or heterocyclic aromatic group with one or more rings; and B represents a hydrogen atom, a lower aliphatic group with 1-3 carbon atoms or a phenyl group; or, when m represents 0, A and B together represent a bivalent homocyclic or heterocyclic aromatic group with two or more rings, or a methylidene group carrying as a substituent a homocyclic or heterocyclic aromatic group with one or more rings; an aromatic ring of A, or of A and B together, optionally carrying one to three substituents selected from lower alkoxy groups, lower alkyl alkenyl groups, formyl or acetyl groups, hydroxy groups or acyloxy groups, and halogen atoms; C represents a hydrogen atom or an alkyl group or, when m represents 0, a hydroxy or alkoxy group; D represents an oxygen or sulphur atom; X+ represents a hydrogen ion or another physiologically compatible cation; with the proviso that m represents 1 when S represents a substituted or unsubstituted phenyl group and Band C both represent hydrogen atoms; or when A represents an unsubstituted phenyl group, B represents an alkyl group and C represents a hydrogen atom.

  通过加入至少一种通式(I)化合物，可降低含有相对大量甜味剂糖或糖醇的可食用产品或口服组合物的甜度和/或增强其风味 其中，m 代表 0 或 1，A 代表具有一个或多个环的均环或杂环芳香基团；B 代表氢原子、具有 1-3 个碳原子的低级脂肪族基团或苯基；或者，当 m 代表 0 时，A 和 B 共同代表具有两个或多个环的二价均环或杂环芳香基团，或者代表以具有一个或多个环的均环或杂环芳香基团为取代基的亚甲基；A 的芳香环，或 A 和 B 的芳香环，可选择带有一至三个取代基，这些取代基选 自低级烷氧基、低级烷基烯基、甲酰基或乙酰基、羟基或酰氧基以及卤素原子； C 代表氢原子或烷基，或当 m 代表 0 时，代表羟基或烷氧基； D 代表氧原子或硫原子； X+ 代表氢离子或其他生理上相容的阳离子； 但当 S 代表取代或未取代的苯基且带 C 均代表氢原子时，或当 A 代表未取代的苯基，B 代表烷基且 C 代表氢原子时，m 代表 1。
• Pharmaceutical compositions comprising a bisphosphonate and vitamin D
  申请人：Novartis AG

  公开号：EP1972341A1

  公开（公告）日：2008-09-24

  Parenteral pharmaceutical compositions comprising vitamin D, or a bisphosphonate and vitamin D for treatment or prevention of diseases of abnormally increased bone turnover and/or vitamin D deficiency.

  由维生素 D 或双膦酸盐和维生素 D 组成的肠外药物组合物，用于治疗或预防骨转换异常增加和/或维生素 D 缺乏症。
• ADIPONECTIN RECEPTOR-ACTIVATING COMPOUND
  申请人：The University of Tokyo

  公开号：EP3053911A1

  公开（公告）日：2016-08-10

  An AdipoR activator for activating both AdipoR1 and AdipoR2 is provided. A compound represented by the following formula (1), wherein A is a substituted or unsubstituted aryl group or the like, Y1 is (CHR2)a- or the like, X is CH or N, R1 is a C1-7 alkyl group, m is an integer of 0-4, Y2 is *-O-CH2-CONH-, *-CONH-(CH2)b-CO- or the like, Z is a cyclic group, B may be a substituent of the cyclic group represented by Z, and n is an integer of 0-3.

  本发明提供了一种可同时激活 AdipoR1 和 AdipoR2 的 AdipoR 激活剂。一种由下式（1）代表的化合物，其中 A 是取代或未取代的芳基或类似物，Y1 是 (CHR2)a- 或类似物，X 是 CH 或 N，R1 是 C1-7 烷基，m 是 0-4 的整数，Y2 是 *-O-CH2-CONH-、*-CONH-(CH2)b-CO- 或类似物，Z 是环状基团，B 可以是 Z 所代表的环状基团的取代基，n 是 0-3 的整数。

表征谱图